Regulonix Holding
Dr. Patwardhan has over 15 years’ experience in pain pharmacology, both preclinical and clinical, and has published more than 30 peer reviewed papers with studies funded by NIH and the Foundation for Anesthesia Education and Research. Dr. Patwardhan regularly serves as a translational pain expert on panels formed by the NIH (NINDS) and the Department of Defense (DoD) and serves as a principal investigator on multiple industry sponsored clinical trials in pain patients. He is a founder of a pharmaceutical startup, holds two patents, and serves on scientific advisory board of several pharmaceutical companies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Regulonix Holding
Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. By indirectly targeting the sodium channel NaV1.7 – a well-established and genetically validated pain target – and focusing on the signaling pathways that control this channel’s activity, the Regulonix team has isolated compounds demonstrated in animal models to be non-addictive and more effective than morphine.